Paris and Boston, October 21st, 2020. Ariana® Pharma a leading digital health company today announced the appointment of Kia Motesharei, PhD to its board of directors. Dr. Motesharei joins existing directors Mohammad Afshar, MD, PHD President and CEO, Felix Frueh, PhD, Isabelle Buckle, PhD, Adam Afshar and Daniel Bernier. […]
Paris and Boston, April 17th 2020. Ariana® Pharma a leading digital health company announced today the publication of the first reported genome-wide search for biomarkers associated with drug response in Alzheimer’s disease in the Alzheimer’s & Dementia: Translational Research & Clinical Interventions journal. […]
Big Data analysis of over 125 Million patient hospitalization records using Ariana’s data analytics and AI platform identifies significant factors increasing Case Fatality Rates […]
Ariana’s KEM® Artificial Intelligence technology identified immunological changes, which are early indicators of clinical effects, for selected groups of patients in a first-in-human Phase 1b study. The potential for a selection biomarker in patients receiving this therapy transforms design options for Imcyse’s future clinical trials in T1D and additional indications. […]
Gut Microbiota biomarkers associated with improved drug response, as well as genomic biomarkers for early detection of patients at risk were identified using Ariana’s KEM® Explainable AI (XAI) in 3 separate oral presentations. […]
Ariana® Pharma announces the appointment of Federico Goodsaid, PhD to the position of Senior Vice President for Regulatory Affairs Paris, France and Cambridge,MA – June 18, 2019 – Ariana Pharma (Paris, France and Cambridge, MA), a leading digital health company focused on developing advanced Artificial Intelligence technologies for patient stratification in clinical trials, today announced the appointment of Federico Goodsaid, PhD, to the position of Senior Vice President for Regulatory Affairs. Federico Goodsaid’s appointment as the Senior VP Regulatory Affairs reinforces Ariana’s capability to combine its data analytics technology with regulatory expertise and to translate the findings generated by its Artificial Intelligence platform into innovative [...]
Ariana to present data at AACR 2019 on using its KEM® Artificial Intelligence technology and PDX mouse models to simulate patient stratification in clinical trials and Identify companion biomarkers for combination therapy […]
Precision medicine approach using Ariana’s AI KEM® shows that a small data rich open label clinical study of 32 well-characterized patients may be sufficient to identify strong biomarker hypothesis identifying patients with the highest chance of benefiting from the drug. […]
Ariana Pharma helps Valiseek® demonstrate efficacy of its lung cancer therapy in phase 2 clinical trial. […]
Gastric Cancer: Ariana and academic collaborators from the Gastro Glyco Explorer consortium identify a novel single marker for Microsatellite instability (MSI), a distinct molecular subtype of gastric cancer. […]